Education
About Us
Working with TipRanks
Follow Us
Immuneering Corp. Class A (IMRX)
:IMRX
IMRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $3.83
Previous CloseN/A
Volume3.55M
Average Volume (3M)228.16K
Market Cap
$64.60M
Enterprise Value$36.33M
Total Cash (Recent Filing)-$13.78M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.02
Next Earnings
May 13, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.03
Shares Outstanding35,887,253
10 Day Avg. Volume200,676
30 Day Avg. Volume228,165
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2910.98
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-47.54
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$10.00Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Immuneering News
PremiumCompany Announcements
Immuneering Corp. Reports Promising Cancer Trial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial Phase 2a efficacy data from IMM-1-104 in combination with chemotherapy shows a promising overall response rate of 40% and a disease control rate of 80%.
Leadership And ExpertiseThe appointment of Dr. Igor Matushansky as the CMO brings extensive oncology drug development expertise to the company.
PartnershipsImmuneering announced a clinical supply agreement with Regeneron Pharmaceutical which will enable IMM-1-104 to be tested in combination with Libtayo in a Ph 2A study.
Bears Say
Financial PerformanceIMRX reported an EPS of -$0.58 for 4Q24, lower than consensus of -$0.43 with slightly higher R&D ($0.9M var).
Stock PerformanceDespite the positive data, the stock has surprisingly declined since the announcement.
---
Ownership Overview
30.64% Insiders
5.96% Mutual Funds
1.23% Other Institutional Investors
58.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $1.00 and its highest was $3.83 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $64.60M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on Mar 20, 2025. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.416 by -$0.164.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.53.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 35,887,253 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.416. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Among the largest hedge funds holding Immuneering Corp. Class A’s share is Perceptive Advisors LLC. It holds Immuneering Corp. Class A’s shares valued at 0.
---
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (455.56% Upside)
$10.00 (455.56% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.06%
12-Months-Change
Fundamentals
Return on Equity
-92.51%
Trailing 12-Months
Asset Growth
-48.61%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
---
IMRX Stock 12 Month Forecast
Average Price Target
$10.00
▲(455.56% Upside)
Technical Analysis
Best Analysts Covering IMRX
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-15.89%
reiterated a buy rating 6 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -15.89% per trade.
---